Company Profile
Medexus Pharmaceuticals is a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.
Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Its portfolio also includes Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and auto-immune diseases, Rupall, a prescription allergy medication, GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution. Its portfolio also includes Naproxen, a Pediapharm naproxen suspension, Otixal, a ciprofloxacin and flucinolone acetonide, Trispan, a triamcinolone hexacetonide injectable suspension, and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation
Over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice. Its portfolio also includes Relaxa, an osmotic laxative to treat occasional constipation in adults, Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee, and Calcia Calcium and vitamin D products. Founded in 2000 and based in Toronto, Canada, Medexus Pharmaceuticals was formerly known as Pediapharm Inc. before rebranding in December 2018.